Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
3.320
-0.360 (-9.78%)
At close: Oct 17, 2025, 4:00 PM EDT
3.380
+0.060 (1.81%)
After-hours: Oct 17, 2025, 5:28 PM EDT
Orchestra BioMed Holdings Revenue
Orchestra BioMed Holdings had revenue of $836.00K in the quarter ending June 30, 2025, with 7.46% growth. This brings the company's revenue in the last twelve months to $2.94M, up 41.61% year-over-year. In the year 2024, Orchestra BioMed Holdings had annual revenue of $2.64M, down -4.42%.
Revenue (ttm)
$2.94M
Revenue Growth
+41.61%
P/S Ratio
42.95
Revenue / Employee
$42,057
Employees
70
Market Cap
179.13M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.64M | -122.00K | -4.42% |
Dec 31, 2023 | 2.76M | -773.00K | -21.88% |
Dec 31, 2022 | 3.53M | 4.32M | -551.79% |
Dec 31, 2021 | -782.00K | -6.49M | -113.71% |
Dec 31, 2020 | 5.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OBIO News
- 10 days ago - Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit - GlobeNewsWire
- 6 weeks ago - Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout - GlobeNewsWire
- 7 weeks ago - Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction - GlobeNewsWire
- 2 months ago - Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility - GlobeNewsWire
- 2 months ago - Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings - GlobeNewsWire
- 2 months ago - Orchestra BioMed Announces Pricing of $40 Million Public Offering - GlobeNewsWire